Commentary: A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children.

This document is a commentary on a comparative randomized clinical trial that evaluated the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment for atopic dermatitis in children. The authors commend the study for comparing the effects of these treatments and providing useful data on adverse events. However, they raise concerns about the trial duration, choice of primary outcomes, randomization process, sample size rationale, lack of blinding, implausibility of skin atrophy data, and ethical concerns. The authors suggest that better reporting following the CONSORT statement could have rectified some of these concerns. [Extracted from the article]